Archives

The Maastricht Study is an extensive phenotyping study that focuses on the etiology of type 2 diabetes, its classic complications (cardiovascular disease, nephropathy, neuropathy and retinopathy), and its emerging comorbidities, including cognitive decline, depression, and gastrointestinal, respiratory and musculoskeletal diseases. The study uses advanced state-of-the-art imaging techniques and extensive biobanking to determine health status in a population-based cohort of 10,000 individuals that is enriched with type 2 diabetes participants. The Maastricht Study is expected to become one of the most extensive phenotyping studies in both the general population and type 2 diabetes participants worldwide.

The Maastricht Study allows researchers access to data to encourage publications of high quality papers and presentations. External researchers (those without an MUMC or UM affiliation) can only submit a research proposal in cooperation with a member of the Maastricht Study Management Team and/or Maastricht Study Participating researchers.

The Maastricht Aging Study (MAAS) was designed to specify the usual and pathological aging of cognitive function. MAAS is devoted to the age-related decline of memory and other cognitive functions in normal people and the factors that may be involved in this process. What determines a decline in memory function? Why do some individuals show a greater decline than others? Over the past years, a host of factors, including biological, medical, psychological and social variables, have been proposed to have an impact on adult cognitive development. MAAS tries to study these factors in an integrative way. This can be achieved only by studying large numbers of normal healthy adults of all ages and by monitoring them for several years.